Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors
Neurotoxicity in Primary Central Nervous System Lymphoma (PCNSL): An International Observational Study of Cognition in Long Term Survivors
This research is being done to investigate cognition in long term survivors of Primary
 Central Nervous System Lymphoma (PCNSL). Sometimes caregivers as well as patients who no
 longer have the disease report cognitive problems such as reduced memory or attentional
 dysfunction and decreased quality of life. Unfortunately, little is known about what may
 contribute to this cognitive dysfunction in part because PCNSL is a rare disease and
 sensitive tests have not often been used in the research studies. This project is being
 conducted to help understand what factors, such as radiation, may contribute to cognitive
 dysfunction and better define the relationship between brain structure and thinking in people
 who have had PCNSL.
This is an international, multi-center project that will enroll as many as 118 subjects of
 which approximately 35 will be enrolled at Oregon Health & Science University (OHSU).
 Neuropsychological testing will consist of a battery of paper and pencil tests that examine
 abilities such as memory, motor skills, attention and speed of information processing.
 Questionnaires that assess quality of life will also be administered. These noninvasive tests
 are administered by a trained examiner or neuropsychologist and last about 30 minutes.
 Subjects will also undergo an MRI of the head which provides a picture of the brain's
 structure by placing an individual inside a powerful magnet. Statistical analyses will
 examine the relationship between the neuropsychological test scores and magnetic resonance
 (MR) images as well as examine the contribution of factors such as radiation, age, surgery,
 chemotherapy etc. to cognition.
Inclusion Criteria:

 -  Radiological and histological diagnosis of PCNSL

 -  Age 18 years or older

 -  Survived 2 years or more following treatment

 -  Able to complete neuropsychological and neuroimaging parts of the study

 -  Signed a written informed consent in accordance with institutional guidelines

 Exclusion Criteria:

 -  Subject has experienced recurrent disease

 -  Subject has a contraindication for MRI

 -  Subject has a contraindication for neuropsychological testing

 -  Subject has stage IV or V renal insufficiency